Numab to receive first milestone payment
Boehringer Ingelheim has advanced its novel tumor antigen targeting T cell engager resulting from a collaboration with Numab into preclinical development
HORGEN, Switzerland, Sept. 25, 2025("Numab"), a biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, announced today that Boehringer Ingelheim has advanced its novel T cell engager for the treatment of lung and gastrointestinal (GI) cancers resulting from a collaboration with Numab into preclinical development. The milestone achievement triggers a payment to Numab as part of the agreement.
Lung cancer is the world's most common and deadliest cancer, while GI cancers, including colorectal and stomach cancers, make up a large share of global cases and deaths. Boehringer Ingelheim aims to address these challenges by pioneering life-changing innovations in areas of high unmet need to transform cancer care.
In 2020, Numab and Boehringer Ingelheim entered into a research collaboration and worldwide licensing agreement on two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers, as well as patients with wet age-related macular degeneration (AMD), a progressive, irreversible retinal disease. The collaboration brings together Boehringer Ingelheim's leading expertise in the research and development of life changing breakthrough therapies with Numab's multi-specific antibody platform.
"We are pleased that Boehringer has decided to move forward with the development of our novel T cell engager into preclinical studies, generating a milestone payment to Numab," said Angehrn Pavik, CEO of Numab. "We are also excited that the potential of our antibody platform continues to be recognized by international Pharma partners and highlights our team's strong commitment to pursuing regional and global development collaborations, in addition to our proprietary programs."
AboutNumabTherapeutics AG
Numab Therapeutics AG is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms ?-CapTM and MATCHTM puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of new and important medicines aimed to maximize patient benefits. Numab's diverse research pipeline spans multiple therapeutic areas and creates the opportunity for the next generation of first-in-class and best-in-class medicines. For further information, visit https://www.numab.com.
For further details, please contact:
Numab Therapeutics
Barbara Angehrn Pavik
Chief Executive Officer
b.angehrn@numab.com
Numab Investor Contact:
Patrick Till
Meru Advisors
ptill@meruadvisors.com
